GlassScriptPhysician profile
Megan Martin
NPI 1386061117
$6,544.92
in general payments reported to CMS, 2019-2025
71 companies · $1,470 in 2025
The $1,470 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,265 · 2022: $1,390 · 2023: $1,267 · 2024: $1,153 · 2025: $1,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,889.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,231.42 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $796.64 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $275.18 | 2021-2025 | Rexulti |
| Insulet Corporation | $246.19 | 2021-2024 | Omnipod |
| Amgen INC. | $239.16 | 2021-2025 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $209.41 | 2021-2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $181.24 | 2021-2023 | Belsomra, Gardasil 9, Steglatro |
| Tandem Diabetes Care, INC. | $178.64 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $178.60 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.40 | 2021-2025 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $138.52 | 2021-2025 | Recorlev |
| Esperion Therapeutics, INC. | $132.21 | 2021-2024 | Nexletol |
| Dexcom, INC. | $130.64 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $128.28 | 2022-2023 | Xarelto |
| Emd Serono, INC. | $114.39 | 2024-2025 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.